William Blair reduced their Q1 2026 EPS estimates for Bristol-Myers Squibb in a research report issued to clients and ...
A weekly summary of insider trading highlighting a few notable buying and selling by investors, directors and executives. The ...
Exelixis, Inc. (NASDAQ:EXEL) authorized repurchasing up to an additional $500 million of the company’s common stock before December 31, 2025. Exelixis plans to complete the $500 million stock ...
Bristol-Myers Squibb released financial results for Q4 2024. Check out why I am upgrading BMY stock's rating from 'Buy' to ...
The Healthcare sector of the economy is front and center on Friday as shares of UnitedHealth drop 7.8%, spurring a widespread market selloff across the broader market a ...
Stocktwits on MSN2d
Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board?JPMorgan is sticking with Eli Lilly (LLY) as its top biopharma pick for 2025, while also highlighting Gilead Sciences (GILD) ...
Bristol Myers Squibb Co. said Cari Gallman, the company’s executive vice president for corporate affairs, will become its ...
NICE's initial guidance on Breyanzi concluded it was not a cost-effective option for patients, but the agency said this ...
Sweden’s BioArctic today revealed that the US Federal Trade Commission (FTC) has cleared the proposed deal with Bristol Myers ...
Noninvasive monitoring methods, such as enterography and ultrasound, are becoming increasingly recognized as essential tools ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback